tetano
Editor, Senior Moderator
Med Drug Discov. 2020 Apr 13:100037. doi: 10.1016/j.medidd.2020.100037. [Epub ahead of print]
Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies.
Liao J[SUP]1[/SUP], Way G[SUP]1[/SUP], Madahar V[SUP]1[/SUP].
Author information
Abstract
The COVID-19 pandemic, after it was reported in December 2019, is a highly contagious and now spreading to over 190 countries, causing a severe public health burden. Currently, there is no vaccine or specific drug to treat COVID-19, which is caused by a novel coronavirus, SARS-2-CoV. For this emergency, the FDA has approved Remdesivir and Hydroxychloroquine for treatment of COVID-19 as Emergency Use Authorization. However, even after this pandemic, COVID-19 may still have a chance to come back. Therefore, we need to come out with new strategies for drug discovery for combating COVID-19 in the future.
? 2020 Published by Elsevier B.V.
KEYWORDS:
COVID-19; Host factor; Influenza virus; SARS-CoV-2; Therapeutics; drug discovery
PMID:32292909PMCID:PMC7153514DOI:10.1016/j.medidd.2020.100037
Free PMC Article
Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies.
Liao J[SUP]1[/SUP], Way G[SUP]1[/SUP], Madahar V[SUP]1[/SUP].
Author information
Abstract
The COVID-19 pandemic, after it was reported in December 2019, is a highly contagious and now spreading to over 190 countries, causing a severe public health burden. Currently, there is no vaccine or specific drug to treat COVID-19, which is caused by a novel coronavirus, SARS-2-CoV. For this emergency, the FDA has approved Remdesivir and Hydroxychloroquine for treatment of COVID-19 as Emergency Use Authorization. However, even after this pandemic, COVID-19 may still have a chance to come back. Therefore, we need to come out with new strategies for drug discovery for combating COVID-19 in the future.
? 2020 Published by Elsevier B.V.
KEYWORDS:
COVID-19; Host factor; Influenza virus; SARS-CoV-2; Therapeutics; drug discovery
PMID:32292909PMCID:PMC7153514DOI:10.1016/j.medidd.2020.100037
Free PMC Article